Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally.
Moderate growth potential with imperfect balance sheet.
Share Price & News
How has Akorn's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AKRX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AKRX underperformed the US Pharmaceuticals industry which returned -12.4% over the past year.
Return vs Market: AKRX underperformed the US Market which returned -12.7% over the past year.
Price Volatility Vs. Market
How volatile is Akorn's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StAkorn, Inc.'s (NASDAQ:AKRX) Path To Profitability
1 month ago | Simply Wall StSome Akorn (NASDAQ:AKRX) Shareholders Have Copped A 97% Share Price Wipe Out
2 months ago | Simply Wall StHow Does Akorn, Inc. (NASDAQ:AKRX) Affect Your Portfolio Volatility?
Is Akorn undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AKRX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AKRX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AKRX is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: AKRX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AKRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AKRX is good value based on its PB Ratio (0.3x) compared to the US Pharmaceuticals industry average (2.4x).
How is Akorn forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AKRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: AKRX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AKRX's is expected to become profitable in the next 3 years.
Revenue vs Market: AKRX's revenue (1.8% per year) is forecast to grow slower than the US market (7.3% per year).
High Growth Revenue: AKRX's revenue (1.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AKRX's Return on Equity is forecast to be high in 3 years time
How has Akorn performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AKRX is currently unprofitable.
Growing Profit Margin: AKRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AKRX is unprofitable, and losses have increased over the past 5 years at a rate of -62.4% per year.
Accelerating Growth: Unable to compare AKRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AKRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.2%).
Return on Equity
High ROE: AKRX has a negative Return on Equity (-96.79%), as it is currently unprofitable.
How is Akorn's financial position?
Financial Position Analysis
Short Term Liabilities: AKRX's short term assets ($480.0M) do not cover its short term liabilities ($985.6M).
Long Term Liabilities: AKRX's short term assets ($480.0M) exceed its long term liabilities ($68.8M).
Debt to Equity History and Analysis
Debt Level: AKRX's debt to equity ratio (359.9%) is considered high.
Reducing Debt: AKRX's debt to equity ratio has increased from 314.9% to 359.9% over the past 5 years.
Inventory Level: AKRX has a high level of physical assets or inventory.
Debt Coverage by Assets: AKRX's debt is not covered by short term assets (assets are 0.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AKRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AKRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of -28.3% each year
What is Akorn's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AKRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AKRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AKRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AKRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AKRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Doug Boothe (55yo)
Mr. Douglas S. Boothe, also known as Doug, is President and Chief Executive Officer of Akorn, Inc since January 1, 2019 and serves as its Director since January 28, 2019. Mr. Boothe was President of Impax ...
|Executive VP & CFO||4.42yrs||US$1.69m||0.027% $21.8k|
|Executive VP||11.17yrs||US$2.10m||0.37% $303.7k|
|Executive VP & Chief Commercial Officer||1.25yrs||US$1.16m||0.0035% $2.8k|
|President||1.17yrs||no data||0.37% $299.9k|
|Executive Vice President of Global Operations||1.17yrs||no data||no data|
|Senior VP of Finance & Chief Accounting Officer||4.58yrs||US$1.41m||0.0084% $6.9k|
|Senior Vice President of Corporate Strategy & Investor Relations||no data||no data||no data|
|Senior Vice President of Corporate Development||3.58yrs||no data||no data|
|Chief Human Resources Officer||4.17yrs||no data||no data|
|Senior Vice President of National Accounts & Trade Relations||15.42yrs||US$759.53k||no data|
Experienced Management: AKRX's management team is considered experienced (4.2 years average tenure).
|President||1.17yrs||no data||0.37% $299.9k|
|Independent Director||4.92yrs||US$397.48k||0.017% $13.9k|
|Independent Chairman of the Board||3.17yrs||US$439.98k||0.11% $86.9k|
|Independent Director||9.83yrs||US$364.98k||0.029% $23.4k|
|Independent Director||8yrs||US$384.98k||0.025% $20.0k|
|Independent Director||1.17yrs||no data||no data|
|Independent Director||10.75yrs||US$372.48k||0.19% $152.4k|
Experienced Board: AKRX's board of directors are considered experienced (6.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AKRX insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Akorn, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Akorn, Inc.
- Ticker: AKRX
- Exchange: NasdaqGS
- Founded: 1971
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$81.201m
- Shares outstanding: 126.25m
- Website: https://www.akorn.com
Number of Employees
- Akorn, Inc.
- 1925 West Field Court
- Suite 300
- Lake Forest
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AKRX||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Apr 1988|
|FDA||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Apr 1988|
|FDA||BRSE (Berne Stock Exchange)||Yes||Common Shares||CH||CHF||Apr 1988|
Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/30 01:31|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.